IT Versione italiana

press conferences » Retinal diseases: the CATT Study and the emerging treatments


A difficult choice: lower costs vs. fewer side effects

From 16.05.2012 to 16.05.2012    Milano, Circolo della Stampa

The Novartis press conference addresses issues related to the treatment of degenerative diseases of the macula and retinal diseases and their impact on the quality of life.  The CATT Study compares two different molecules (ranibizumab and bevacizumab), and focuses on the different side effects.



presentations

[it] Introduction - Susanna Petruni TG1 (RAI)
[it] The impact of retinal diseases
Prof. Filippo Cruciani
[it] Hyper vision and blindness
Prof. Filippo Cruciani
[it] Macular Degeneration: impact on quality of life
Prof. Filippo Cruciani
[it] Retinal diseases and economic social impact
Prof. Filippo Cruciani
[it] Macular degeneration does not cause blindness
Prof. Francesco Bandello
[it] Age related Macular Degeneration: the treatments
Prof. Francesco Bandello
[it] C.A.T.T. Trial: the side effects
Prof. Francesco Bandello
[it] Economic savings or minimum side effects: a difficult choice
Prof. Francesco Bandello
[it] Questions & answers - 1st part
[it] Questions & answers - 2nd part
[it] Questions & answers - 3rd part

highlights

[it] Retinal diseases: patients and quality of life
Prof. Filippo Cruciani
[it] Diabetic macular edema
Prof. Francesco Bandello


Cookies helps us to provide our services. Using these services , you agree to use of cookies on our part. OK